Loading...

Rahul Aggarwal, MD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone415-353-9278
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Northwestern University FeinbergM.D.2006School of Medicine
    University of California, San FranciscoResidency 2009School of Medicine - Internal Medicine
    University of California, San FranciscoFellowship2013Hematology/Oncology
    Collapse Awards and Honors
    2011  - 2012Pfizer Fellowship in Oncology
    2012  - 2013ASCO Young Investigator Award
    2013Alliance Cooperative Group Scholar Award
    2015  - 2017Prostate Cancer Foundation Young Investigator Award
    2016Department of Defense Prostate Cancer Program Physician Research Training Award
    2016  - 2019Department of Defense Prostate Cancer Program Idea Development Award
    National Cancer Institute2016  - 2017Cancer Clinical Investigator Team Leadership Award

    Collapse Overview 
    Collapse Overview
    I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco. My clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer. I serve as the Co-Leader for the GU Medical Oncology program at UCSF.

    My research focus is on developing novel therapies and imaging modalities for patients with advanced solid tumor malignancies, with a focus on patients with advanced prostate cancer.

    Collapse Research 
    Collapse Research Activities and Funding
    Precision targeting of T cell cytotoxicity with PET
    NIH R01CA258297Mar 1, 2021 - Feb 28, 2026
    Role: Co-Principal Investigator
    Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring
    NIH R01CA256740Dec 1, 2020 - Nov 30, 2025
    Role: Co-Principal Investigator
    Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer
    NIH R01CA229354Jun 1, 2019 - Apr 30, 2021
    Role: Principal Investigator
    Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring
    NIH R01CA215694Jun 1, 2017 - May 31, 2022
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse In The News
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Differential Treatment Outcomes in BRCA1/2-, CDK12-, and ATM-Mutated Metastatic Castration-Resistant Prostate Cancer. Cancer. 2021 Mar 10. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. PMID: 33690902.
      View in: PubMed   Mentions:    Fields:    
    2. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Sci Rep. 2021 Mar 03; 11(1):5040. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS. PMID: 33658587.
      View in: PubMed   Mentions:    Fields:    
    3. Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models. Metabolites. 2021 Feb 26; 11(3). Sun J, Bok RA, DeLos Santos J, Upadhyay D, DeLos Santos R, Agarwal S, Van Criekinge M, Vigneron DB, Aggarwal R, Peehl DM, Kurhanewicz J, Sriram R. PMID: 33652703.
      View in: PubMed   Mentions:
    4. Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry. Ann Oncol. 2021 05; 32(5):678-679. PMID: 33571636.
      View in: PubMed   Mentions:    Fields:    
    5. Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy. Proc Natl Acad Sci U S A. 2021 Jan 26; 118(4). Chen W, Mou KY, Solomon P, Aggarwal R, Leung KK, Wells JA. PMID: 33483421.
      View in: PubMed   Mentions: 1     Fields:    
    6. Prime Time for Consultation Audio Recordings: Supporting Shared Decision Making During and After the COVID-19 Era. JCO Oncol Pract. 2020 Dec 17; OP2000765. Kwon DH, Aggarwal RR, Esserman LJ, Belkora JK. PMID: 33332174.
      View in: PubMed   Mentions:
    7. Molecular imaging of prostate cancer targeting CD46 using immunoPET. Clin Cancer Res. 2020 Dec 08. Wang S, Li J, Hua J, Su Y, Beckford Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J. PMID: 33293372.
      View in: PubMed   Mentions:    Fields:    
    8. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 Dec 01; 26(23):6204-6214. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. PMID: 32967941.
      View in: PubMed   Mentions:    Fields:    
    9. The synthesis and structural requirements for measuring glucocorticoid receptor expression in vivo with (±)-11C-YJH08 PET. J Nucl Med. 2020 Sep 04. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Parker MFL, Blecha JE, Drake CR, VanBrocklin HF, Ruiz DG, Jacobson MP, Aggarwal R, Behr SC, Flavell RR, Wilson DM, Seo Y, Evans MJ. PMID: 32887758.
      View in: PubMed   Mentions:    Fields:    
    10. Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. Ther Adv Med Oncol. 2020; 12:1758835920936084. Han HJ, Li YR, Roach M, Aggarwal R. PMID: 32922519.
      View in: PubMed   Mentions:
    11. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 Sep 01; 26(17):4616-4624. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. PMID: 32727885.
      View in: PubMed   Mentions:    Fields:    
    12. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2020 Oct 15; 26(20):5338-5347. Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, Lakhotia S, Feng FY, Small EJ, Abida W, Alumkal JJ. PMID: 32694156.
      View in: PubMed   Mentions: 2     Fields:    
    13. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 08; 52(8):778-789. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. PMID: 32661416.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    14. Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urol Oncol. 2020 Dec; 38(12):931.e9-931.e16. Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small EJ, Aggarwal RR. PMID: 32624423.
      View in: PubMed   Mentions:    Fields:    
    15. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci U S A. 2020 06 02; 117(22):12315-12323. Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. PMID: 32424106.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    16. Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer. Am Soc Clin Oncol Educ Book. 2020 May; 40:e319-e332. Carneiro BA, Lotan TL, de Souza A, Aggarwal R. PMID: 32479115.
      View in: PubMed   Mentions:    Fields:    
    17. A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chem Biol. 2020 06 19; 15(6):1381-1391. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Blecha JE, VanBrocklin HF, Seo Y, Sayeed M, Feldman BJ, Aggarwal R, Behr SC, Shao H, Wilson DM, Villanueva-Meyer JE, Gestwicki JE, Evans MJ. PMID: 32255605.
      View in: PubMed   Mentions:    Fields:    
    18. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020 Apr 14. Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, Feng F, Stuart JM, Small EJ. PMID: 32286548.
      View in: PubMed   Mentions: 2     Fields:    
    19. Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm. Mol Imaging Biol. 2020 02; 22(1):208-216. Seo Y, Khalighi MM, Wangerin KA, Deller TW, Wang YH, Jivan S, Kohi MP, Aggarwal R, Flavell RR, Behr SC, Evans MJ. PMID: 30993558.
      View in: PubMed   Mentions:    Fields:    
    20. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer Prostatic Dis. 2020 06; 23(2):316-323. Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, Alumkal JJ, Gleave M, Chi KN, Reiter RE, Rettig MB, Evans CP, Small EJ, Sharifi N, Zhao SG. PMID: 31745256.
      View in: PubMed   Mentions: 1     Fields:    
    21. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urol Oncol. 2020 03; 38(3):83-93. Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ. PMID: 31734020.
      View in: PubMed   Mentions:    Fields:    
    22. Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. Prostate Cancer Prostatic Dis. 2020 06; 23(2):269-276. Chen HY, Aggarwal R, Bok RA, Ohliger MA, Zhu Z, Lee P, Gordon JW, van Criekinge M, Carvajal L, Slater JB, Larson PEZ, Small EJ, Kurhanewicz J, Vigneron DB. PMID: 31685983.
      View in: PubMed   Mentions: 4     Fields:    
    23. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 11; 76(5):562-571. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ. PMID: 30928160.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    24. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 06; 17(6):1235-1240. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. PMID: 30918106.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    25. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer. 2019 Mar 04; 19(1):196. Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B. PMID: 30832606.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    26. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):531-538. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. PMID: 30804427.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    27. Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies. J Magn Reson. 2019 04; 301:73-79. Zhu Z, Zhu X, Ohliger MA, Tang S, Cao P, Carvajal L, Autry AW, Li Y, Kurhanewicz J, Chang S, Aggarwal R, Munster P, Xu D, Larson PEZ, Vigneron DB, Gordon JW. PMID: 30851668.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    28. Reply to A. Dalla Volta et al. J Clin Oncol. 2019 02 01; 37(4):351-352. Aggarwal R, Huang J, Alumkal J, Feng FY, Zhang L, Stuart JM, Small EJ. PMID: 30557523.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. J Nucl Med. 2019 07; 60(7):910-916. Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. PMID: 30464040.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    30. Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. Magn Reson Med. 2019 04; 81(4):2702-2709. Gordon JW, Chen HY, Autry A, Park I, Van Criekinge M, Mammoli D, Milshteyn E, Bok R, Xu D, Li Y, Aggarwal R, Chang S, Slater JB, Ferrone M, Nelson S, Kurhanewicz J, Larson PEZ, Vigneron DB. PMID: 30375043.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    31. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 10 18; 175(3):889. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30340047.
      View in: PubMed   Mentions: 14     Fields:    
    32. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study. Clin Genitourin Cancer. 2019 Feb; 17(1):e92-e96. Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R. PMID: 30327180.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    33. Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients. NMR Biomed. 2018 11; 31(11):e3997. Larson PEZ, Chen HY, Gordon JW, Korn N, Maidens J, Arcak M, Tang S, Criekinge M, Carvajal L, Mammoli D, Bok R, Aggarwal R, Ferrone M, Slater JB, Nelson SJ, Kurhanewicz J, Vigneron DB. PMID: 30230646.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    34. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 09 06; 3(17). Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. PMID: 30185663.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    35. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 07 26; 174(3):758-769.e9. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30033370.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    36. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 08 20; 36(24):2492-2503. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. PMID: 29985747.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCellsCTClinical Trials
    37. Spatio-Temporally Constrained Reconstruction for Hyperpolarized Carbon-13 MRI Using Kinetic Models. IEEE Trans Med Imaging. 2018 12; 37(12):2603-2612. Maidens J, Gordon JW, Chen HY, Park I, Van Criekinge M, Milshteyn E, Bok R, Aggarwal R, Ferrone M, Slater JB, Kurhanewicz J, Vigneron DB, Arcak M, Larson PEZ. PMID: 29994332.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    38. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018 05; 1(1):78-82. Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. PMID: 31100231.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    39. Technique development of 3D dynamic CS-EPSI for hyperpolarized 13 C pyruvate MR molecular imaging of human prostate cancer. Magn Reson Med. 2018 11; 80(5):2062-2072. Chen HY, Larson PEZ, Gordon JW, Bok RA, Ferrone M, van Criekinge M, Carvajal L, Cao P, Pauly JM, Kerr AB, Park I, Slater JB, Nelson SJ, Munster PN, Aggarwal R, Kurhanewicz J, Vigneron DB. PMID: 29575178.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    40. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2018 06; 23(6):656-e64. Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ. PMID: 29487219.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    41. Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018 05; 73(5):694-695. Aggarwal R. PMID: 29458985.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    42. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 01; 109(12). Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. PMID: 29206995.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    43. Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers. Eur Urol. 2018 06; 73(6):845-846. Aggarwal R. PMID: 29128209.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer. Lancet Oncol. 2017 11; 18(11):1436-1437. Aggarwal R. PMID: 29033098.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets. Eur Urol. 2018 02; 73(2):306-307. Brzezniak C, Oronsky B, Aggarwal R. PMID: 28943185.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    46. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer. 2017 09 19; 5(1):75. Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, Jablons D. PMID: 28923100.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    47. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. PMID: 28893315.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    48. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. PMID: 28790114.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsCTClinical Trials
    49. Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer. Eur Urol. 2017 12; 72(6):1028-1029. Aggarwal R, Vigneron DB, Kurhanewicz J. PMID: 28765011.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    50. Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications. Oncology (Williston Park). 2017 06 15; 31(6):467-74. Aggarwal RR, Feng FY, Small EJ. PMID: 28620903.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    51. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res. 2017 09; 15(9):1221-1229. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. PMID: 28592703.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    52. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):733-741.e1. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. PMID: 28655452.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    53. CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. J Vasc Interv Radiol. 2017 Aug; 28(8):1073-1081.e1. Holmes MG, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, Alumkal JJ, Beer TM, Small EJ, Link TM. PMID: 28549709.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    54. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 12; 58(12):1956-1961. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. PMID: 28522741.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    55. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 09; 7(9):999-1005. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. PMID: 28450426.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    56. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget. 2017 Sep 22; 8(42):71447-71455. Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV. PMID: 29069718.
      View in: PubMed   Mentions: 4     Fields:    
    57. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Eur Urol. 2017 07; 72(1):34-42. Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW. PMID: 28259476.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    58. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017 Apr 10; 35(11):1231-1239. Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. PMID: 28221861.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    59. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 04; 35(4):149.e7-149.e13. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. PMID: 28161323.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    60. Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience. Mol Imaging. 2017 Jan-Dec; 16:1536012117723256. Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ. PMID: 28893116.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Mol Imaging Biol. 2016 12; 18(6):946-951. Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, Small EJ, Evans MJ. PMID: 27184068.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    62. Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. Eur Urol Focus. 2016 Dec; 2(5):469-471. Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, Small EJ. PMID: 28723508.
      View in: PubMed   Mentions: 4     Fields:    
    63. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017 Jan; 58(1):81-84. Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. PMID: 27660139.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    64. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. Future Oncol. 2016 Nov; 12(21):2393-2396. Hope TA, Aggarwal RR, Westphalen AC, Cooperberg MR, Greene KL. PMID: 27453303.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    65. Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure? Eur Urol. 2016 09; 70(3):445-6. Aggarwal R. PMID: 26992281.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. Approaches to minimize castration in the treatment of advanced prostate cancer. Urol Oncol. 2016 08; 34(8):368-74. Zejnullahu K, Arevalo MG, Ryan CJ, Aggarwal R. PMID: 26944450.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    67. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016 05; 27(5):947-52. Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. PMID: 26903311.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    68. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. PMID: 26603258.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    69. Somatostatin imaging of neuroendocrine-differentiated prostate cancer. Clin Nucl Med. 2015 Jun; 40(6):540-1. Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ. PMID: 25783510.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    70. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. PMID: 25557266.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    71. Small-cell/neuroendocrine prostate cancer: a growing threat? Oncology (Williston Park). 2014 Oct; 28(10):838-40. Aggarwal RR, Small EJ. PMID: 25323608.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    72. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. Cancer Chemother Pharmacol. 2014 Aug; 74(2):359-65. Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P. PMID: 24934865.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    73. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw. 2014 May; 12(5):719-26. Aggarwal R, Zhang T, Small EJ, Armstrong AJ. PMID: 24812138.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    74. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer. 2014 Oct; 12(5):e167-72. Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ. PMID: 24787968.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    75. The changing role of imaging in clinical care. Nat Rev Urol. 2014 Feb; 11(2):75-7. Aggarwal R, Kurhanewicz J. PMID: 24418808.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    76. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Oct 15; 119(20):3636-43. Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ, . PMID: 23913744.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    77. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? Urol Oncol. 2013 Jul; 31(5):522-30. Aggarwal RR, Ryan CJ, Chan JM. PMID: 21658978.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    78. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist. 2011; 16(3):264-75. Aggarwal R, Ryan CJ. PMID: 21339259.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    79. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer. 2009 Oct; 7(3):E71-6. Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. PMID: 19815485.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    Rahul's Networks
    Concepts (268)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (112)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (59)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑